Tag: X

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

This is not just any old birthday party – it’s a month-long extravaganza filled with panda-tastic surprises, Insta-worthy moments, and a chance to take home your very own LABUBU x Panda Twins.

為期一個月的非凡生日慶典，當中滿載驚喜連連的熊貓主題活動、話題打卡時刻，還有贏取限量版LABUBU x Panda Twins的珍貴機會

KOŠICE, Slovakia, July 26, 2025 (GLOBE NEWSWIRE) -- Remittix (RTX), a crypto payments project focused on practical financial utility, has officially announced the Q3 2025 launch of its beta wallet featuring Solana and Ethereum integration. The news follows strong momentum in its presale phase, which has now exceeded $17.3 million in contributions and 573 million tokens sold.

KOŠICE, Slovakia, July 26, 2025 (GLOBE NEWSWIRE) -- Remittix (RTX), a crypto payments platform aiming to simplify cross-border and freelance transactions, has confirmed the Q3 2025 launch of its beta wallet, alongside newly announced integration with the Solana blockchain. These developments mark key milestones in Remittix’s roadmap toward enabling fast, low-cost, and user-friendly crypto-to-fiat payments.

Coinchange Celebrates 4 Years of 'Earn' Product, Marks 7 Years of Growth. The Canadian digital asset management platform reflects on its evolution from retail app to institutional-grade yield infrastructure.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Caribou (CRBU) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Crocs (CROX) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atkore (ATKR)To Contact Him Directly To Discuss Their Options

GEELONG, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that Orion Infrastructure Capital ("OIC") has released US$5 million of the US$25 million facility announced on December 23, 2024. As a result of this release, the full US$25 million facility has now been released. Concurrent with this US$5 million tranche, lenders under the US$60 million PIUS loan entered into in May 2023 (“Existing Noteholders”) have also released the final US$400,000 of existing loan reserves, taking reserves released to US$2 million. In connection with this funding tranche, the Company will issue to OIC and Existing Noteholders, penny warrants to purchase an aggregate number of shares equal to 5.0% of the Company’s shares outstanding.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.